BioAtla, Inc.
General ticker "BCAB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $23.3M (TTM average)
BioAtla, Inc. does not follow the US Stock Market performance with the rate: -33.2%.
Estimated limits based on current volatility of 4.5%: low 1.20$, high 1.46$
Factors to consider:
- Total employees count: 41 (-32.8%) as of 2025
- Top business risk factors: Need additional capital, Limited operating history, No approved products, Pandemic risks, Regulatory and compliance
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [18.52$, 72.31$]
- 2026-12-31 to 2027-12-31 estimated range: [7.94$, 34.97$]
Financial Metrics affecting the BCAB estimates:
- Negative: with PPE of -0.7 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Net income
- Negative: negative Operating cash flow
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of -261.71 <= 7.04
- Negative: Investing cash flow per share per price, % of 0 <= 2.08
- Negative: -0.37 < Inventory ratio change, % of 0
- Negative: negative Industry operating income (median)
Short-term BCAB quotes
Long-term BCAB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $11.00MM | $2.00MM |
| Operating Expenses | $129.69MM | $84.94MM | $61.30MM |
| Operating Income | $-129.69MM | $-73.94MM | $-59.30MM |
| Non-Operating Income | $6.22MM | $4.17MM | $-0.30MM |
| R&D Expense | $103.73MM | $63.09MM | $43.57MM |
| Income(Loss) | $-123.46MM | $-69.78MM | $-59.61MM |
| Net Income(Loss)* | $-123.46MM | $-69.78MM | $-59.61MM |
| Stockholders Equity | $70.67MM | $14.27MM | $-36.19MM |
| Assets | $119.66MM | $52.42MM | $13.83MM |
| Operating Cash Flow | $-104.02MM | $-71.94MM | $-48.20MM |
| Capital expenditure | $0.10MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.10MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $0.08MM | $9.51MM | $6.28MM |
| Earnings Per Share** | $-129.21 | $-71.83 | $-50.66 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.